Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stealth Biotherapeutics Corp

0.3200
0.0000
Volume:- -
Turnover:419.69K
Market Cap:23.54M
PE:-0.35
High:0.3200
Open:0.3200
Low:0.3200
Close:0.3200
52wk High:1.17
52wk Low:0.1621
Shares:73.55M
Float Shares:30.12M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9237
EPS(LYR):-0.9237
ROE:1027.89%
ROA:-67.24%
PB:-0.52
PE(LYR):-0.35

Loading ...

Company Profile

Company Name:
Stealth Biotherapeutics Corp
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate is Elamipretide that is in phase 3 clinical trial to treat barth syndrome, phase 2/3 clinical trial for the treatment of duchenne cardiomyopathy, phase 2a clinical trial to treat friedreich's ataxia, phase 2 clinical trial for the treatment of dry age-related macular degeneration, phase 2 clinical trial to treat leber's hereditary optic neuropathy, and phase 3 clinical trial for the treatment of replisome myopathies. The company's product candidates also include SBT-20 to treat complications of diabetes, renal diseases, ocular diseases, neurodegenerative, Parkinson's, Alzheimer's, Huntington's, and ALS diseases; SBT-550 for rare neurological indications; and SBT-272, a peptidomimetic that targets the mitochondria and stabilizing mitochondrial function under conditions of oxidative stress, as well as SBT 550. Stealth BioTherapeutics Corp was incorporated in 2006 and is based in George Town, the Cayman Islands.